Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs



Rating:

Share or cite this content

Citations should be made in the following way:
T. Ogura (Yokohama, Japan), Y. MORI (Takamatsu, Japan), K. Kataoka (Seto, Japan), O. Nishiyama (Osakasayama, Japan), M. Ando (Nagoya, Japan), S. Arizono (Hamamatsu, Japan), T. Ogawa (Seto, Japan), A. Shiraki (Ogaki, Japan), K. Ichikado (Kumamoto, Japan), H. Ishimoto (Sakamoto, Japan), H. Ito (Kamogawa, Japan), K. Sakamoto (Nagoya, Japan), K. Tomii (Kobe, Japan), H. Tomioka (Kobe, Japan), T. Tsuda (Kitakyusyu, Japan), R. Kozu (Nagasaki, Japan), Y. Kondoh (Seto, Japan). Late Breaking Abstract - Long-term Effect of Pulmonary Rehabilitation under Nintedanib treatment in Idiopathic Pulmonary Fibrosis (FITNESS study). 2905

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF) Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Late Breaking Abstract - BBT-877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Is Pulmonary Rehabilitation A Savior In Idiopathic Pulmonary Fibrosis? Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Treatment of Idiopathic Pulmonary Fibrosis - Executive Summary Source: Guideline 2015 Year: 2015 Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Late Breaking Abstract - First-in-Human Results of Bronchial Rheoplasty: An Endobronchial Treatment For Chronic Bronchitis (CB) Source: International Congress 2018 – Interventional pulmonology highlights in 2018: latest innovations Year: 2018 Late Breaking Abstract - Balloon Pulmonary Angioplasty for the Treatment of Non Operable Chronic Thromboembolic Pulmonary Hypertension – Initial experience of a Belgian Center Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension Year: 2018 Treatment of Idiopathic Pulmonary Fibrosis Source: Guideline 2015 Year: 2015 Late Breaking Abstract - Clinical Efficacy and Safety of Macitentan Transitioned from Bosentan in Patients with Pulmonary Arterial Hypertension Source: International Congress 2018 – Molecular mechanisms and treatment of pulmonary hypertension Year: 2018 A new Humanized Mouse Model for Idiopathic Pulmonary Fibrosis and Effects of Nintedanib Treatment Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Association between Pulmonary Infections and the Prognosis in Patients with Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Pulmonary Alveolar Microlithiasis: From Diagnosis to Transplant: An Indian Experience Source: International Congress 2019 – Lung transplantation: from bench to bedside Year: 2019 Late Breaking Abstract - Endobronchial Valves for Severe Emphysema – 12-month Results of the EMPROVE Trial Source: International Congress 2018 – Interventional pulmonology highlights in 2018: ELVR, TLD and BT Year: 2018 Treatment of Idiopathic Pulmonary Fibrosis - Evidence to Decision Frameworks Source: Guideline 2015 Year: 2015 The Efficacy Of Outpatient Pulmonary Rehabilitation After Bilateral Lung Transplantation; Case Series Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)? Year: 2018 Clinical Correlates of Physical Activity in Idiopathic Pulmonary Fibrosis (IPF) Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 Idiopathic Pulmonary Haemosiderosis; Factors That Effect Prognosis Source: Virtual Congress 2020 – Tip the hat to paediatric bronchology Year: 2020 Tele-rehabilitation program in Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – M-health/e-health I Year: 2019 LATE-BREAKING ABSTRACT: Bosentan in Pulmonary Hypertension associated with Fibrotic Idiopathic Interstitial Pneumonia:A Randomized, Double-Blind, Placebo-controlled Study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013